Adjuvant checkpoint inhibitor trials: is disease-free survival an appropriate endpoint?

HIGHLIGHTS

• who: Ali Raza Khaki and colleagues from the Powered by the California Digital Library University of California have published the research work: Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint?, in the Journal: (JOURNAL)

SUMMARY

Published Works Title Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint? The earlier exposure to ICI monotherapy may lead to resistance and make a patient less sensitive to front-line combinations. Immune related adverse events may occur in just under half of treated patients, including grade 3 or higher events, which can . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.